Back in 2011, when Sanofi acquired Genzyme for about $20 billion, it promised the company's shareholders up to $3.8 billion more tied to the then-in-development multiple sclerosis treatment Lemtrada. Things went awry in 2013 when the FDA rejected the therapy, but a new shareholder lawsuit claims that's just what Sanofi wanted.
Sanofi cautiously waded deeper into RNAi development waters this week, following up on last year's big $700 million buy-in at Alnylam. The pharma giant's Boston subsidiary, Genzyme Sanofi, has picked up some regional rights to the hemophilia treatment ALN-AT3, setting up a complicated set of next steps as Sanofi juggles just what it will opt into and where it wants to leap into commercialization.
Former Genzyme CEO and prolific biotech investor Henri Termeer has stepped in to back another upstart. The biotech legend joined a syndicate that includes Advent Life Sciences and A.M. Pappas in putting up $10 million to fund some crucial proof-of-principle trial work for Artax Biopharma, which believes that it has a unique new key to unlock remedies for autoimmune diseases.
Genzyme agreed to pay the feds $32.5 million for unlawful distribution of its Seprafilm surgical film, on top of the $22.2 million it paid in December 2013 to resolve allegations made under the False Claims Act.
AstraZeneca CEO Pascal Soriot has long argued that shedding some of the company's noncore businesses could help jump-start sales, adding cash to its reservoirs as it chases its lofty sales goals. Now, the British drugmaker is taking another step in that direction as it passes off one of its rare cancer drugs to Sanofi, getting $300 million in the process.
Sanofi's Genzyme is testing an oral drug for Fabry disease, which would go up against its own Fabrazyme if and when it wins approval. But the company knows a thing or two about bringing new pills to market while keeping sales of older drugs intact.
Sanofi's Genzyme is testing an oral drug for Fabry disease, which would go up against its own Fabrazyme if and when it hits the market. But don't worry too much about the pill cannibalizing sales. Judging by the recent success of Genzyme's new oral Gaucher treatment, the company thinks it can find a sizable piece of the Fabry pie for its new pill when the time comes.
Sanofi's rare disease-focused unit Genzyme picked up the FDA's coveted breakthrough-therapy designation for a drug designed to treat a form of Niemann-Pick disease.
Sanofi's rare disease-focused Genzyme picked up the FDA's coveted breakthrough-therapy designation for a candidate designed to treat a form of Niemann-Pick disease.
HBO premiered an award-winning short documentary about Huntington's disease, a rare, hereditary neurological malady, on Monday night. The film follows actress and filmmaker Marianne Palka as she finds out the results of her genetic test. If someone has a parent with the disease as she did, they have a 50/50 chance of getting the disease. The missing voice? Pharma.